Takeda inks $1.7B AI drug deal with Iambic. Potential for huge returns, but early-stage biotech risks loom.
Nikkei 225 futures show mixed price action, with significant volume shifts and open interest drops.
The dollar eased broadly, but Goldman Sachs says Japan’s post-election fiscal outlook keeps USD/JPY upside risks alive. The bank expects volatility to rise, with a move toward 160 lifting intervention risk despite near-term trading caution.
AppLovin (APP) jumps 13% as CapitalWatch retracts claims, boosting confidence despite recent ~37% drop from highs.
Rivian's $45K R2 SUV spotted uncamouflaged! Final tests underway, boosting EV investor hopes.
AJG drops 9.9% on AI threat; valuation now 37% below 52-week high.
Lilly buys Orna for $2.4B, boosting cell therapy pipeline. High valuation signals big growth potential.
Must Read